Cargando…
Effect of antisecretory factor, given as a food supplement to adult patients with severe traumatic brain injury (SASAT): protocol for an exploratory randomized double blind placebo-controlled trial
BACKGROUND: Traumatic brain injury (TBI) constitutes a global epidemic. Overall outcome is poor, with mortality ranging from 10 to 70% and significant long-term morbidity. Several experimental reports have claimed effect on traumatic edema, but no clinical trials have shown effect on edema or outcom...
Autores principales: | Cederberg, David, Harrington, Bradley M., Vlok, Adriaan Johannes, Siesjö, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034076/ https://www.ncbi.nlm.nih.gov/pubmed/35461285 http://dx.doi.org/10.1186/s13063-022-06275-z |
Ejemplares similares
-
Antisecretory Factor May Reduce ICP in Severe TBI—A Case Series
por: Cederberg, David, et al.
Publicado: (2020) -
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
por: Ehinger, Erik, et al.
Publicado: (2023) -
Sampling and sensitivity analyses tools (SaSAT) for computational modelling
por: Hoare, Alexander, et al.
Publicado: (2008) -
Intratumoral administration of the antisecretory peptide AF16 cures murine gliomas and modulates macrophage functions
por: Kopecky, Jan, et al.
Publicado: (2022) -
Chemoprevention of Colonic Polyps with Balsalazide: An Exploratory, Double-Blind, Placebo-Controlled Study
por: Terdiman, Jonathan P., et al.
Publicado: (2009)